139 related articles for article (PubMed ID: 1533435)
1. Perilymphatic injections of recombinant interleukin-2 (rIL-2) partially correct the immunologic defects in patients with advanced head and neck squamous cell carcinoma.
Melioli G; Margarino G; Scala M; Mereu P; Bertoglio S; Schenone G; Barbaresi M; Machí AM; Santi L; Badellino F
Laryngoscope; 1992 May; 102(5):572-8. PubMed ID: 1533435
[TBL] [Abstract][Full Text] [Related]
2. Evidence for local and systemic activation of immune cells by peritumoral injections of interleukin 2 in patients with advanced squamous cell carcinoma of the head and neck.
Whiteside TL; Letessier E; Hirabayashi H; Vitolo D; Bryant J; Barnes L; Snyderman C; Johnson JT; Myers E; Herberman RB
Cancer Res; 1993 Dec; 53(23):5654-62. PubMed ID: 8242620
[TBL] [Abstract][Full Text] [Related]
3. In vivo interleukin 2-induced activation of lymphokine-activated killer cells and tumor cytotoxic T-cells in cervical lymph nodes of patients with head and neck tumors.
Rivoltini L; Gambacorti-Passerini C; Squadrelli-Saraceno M; Grosso MI; Cantù G; Molinari R; Orazi A; Parmiani G
Cancer Res; 1990 Sep; 50(17):5551-7. PubMed ID: 2386961
[TBL] [Abstract][Full Text] [Related]
4. The anti-tumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo: direct correlation between reduction of established metastases and cytolytic activity of lymphokine-activated killer cells.
Mulé JJ; Yang J; Shu S; Rosenberg SA
J Immunol; 1986 May; 136(10):3899-909. PubMed ID: 2871106
[TBL] [Abstract][Full Text] [Related]
5. Local adoptive immunotherapy of human head and neck cancer xenografts in nude mice with lymphokine-activated killer cells and interleukin 2.
Sacchi M; Snyderman CH; Heo DS; Johnson JT; d'Amico F; Herberman RB; Whiteside TL
Cancer Res; 1990 May; 50(10):3113-8. PubMed ID: 2334906
[TBL] [Abstract][Full Text] [Related]
6. Infiltrating leukocyte populations and T-lymphocyte subsets in head and neck squamous cell carcinomas from patients receiving perilymphatic injections of recombinant interleukin 2. A pathologic and immunophenotypic study.
Valente G; De Stefani A; Jemma C; Giovarelli M; Geuna M; Cortesina G; Forni G; Palestro G
Mod Pathol; 1990 Nov; 3(6):702-8. PubMed ID: 2263594
[TBL] [Abstract][Full Text] [Related]
7. Lymphokine-activated killer cells in rats: analysis of progenitor and effector cell phenotype and relationship to natural killer cells.
Vujanovic NL; Herberman RB; Olszowy MW; Cramer DV; Salup RR; Reynolds CW; Hiserodt JC
Cancer Res; 1988 Feb; 48(4):884-90. PubMed ID: 3257412
[TBL] [Abstract][Full Text] [Related]
8. [A phase 2 study of recombinant interleukin 2 (S-6820) for head and neck cancer].
Sawaki S
Gan No Rinsho; 1990 Feb; 36(2):111-20. PubMed ID: 2308207
[TBL] [Abstract][Full Text] [Related]
9. In vivo induction of lymphokine-activated killer cells by interleukin-2 splenic artery perfusion in advanced malignancy.
Klasa RJ; Silver HK; Kong S
Cancer Res; 1990 Aug; 50(16):4906-10. PubMed ID: 2379154
[TBL] [Abstract][Full Text] [Related]
10. Recombinant vaccinia virus expressing interleukin-2 invokes anti-tumor cellular immunity in an orthotopic murine model of head and neck squamous cell carcinoma.
Dasgupta S; Bhattacharya-Chatterjee M; O'Malley BW; Chatterjee SK
Mol Ther; 2006 Jan; 13(1):183-93. PubMed ID: 16125469
[TBL] [Abstract][Full Text] [Related]
11. In vivo effects of recombinant IL-2. I. Isolation of circulating Leu-19+ lymphokine-activated killer effector cells from cancer patients receiving recombinant IL-2.
McMannis JD; Fisher RI; Creekmore SP; Braun DP; Harris JE; Ellis TM
J Immunol; 1988 Feb; 140(4):1335-40. PubMed ID: 3257776
[TBL] [Abstract][Full Text] [Related]
12. Expansion of activated T-lymphocytes in patients treated with recombinant interleukin 2.
Kolitz JE; Welte K; Wong GY; Holloway K; Merluzzi VJ; Engert A; Bradley EC; Konrad M; Polivka A; Gabrilove JL
J Biol Response Mod; 1987 Aug; 6(4):412-29. PubMed ID: 3498011
[TBL] [Abstract][Full Text] [Related]
13. Intratumoral recombinant human interleukin-12 administration in head and neck squamous cell carcinoma patients modifies locoregional lymph node architecture and induces natural killer cell infiltration in the primary tumor.
van Herpen CM; van der Laak JA; de Vries IJ; van Krieken JH; de Wilde PC; Balvers MG; Adema GJ; De Mulder PH
Clin Cancer Res; 2005 Mar; 11(5):1899-909. PubMed ID: 15756016
[TBL] [Abstract][Full Text] [Related]
14. Phase I trial of intraperitoneal recombinant interleukin-2/lymphokine-activated killer cells in patients with ovarian cancer.
Stewart JA; Belinson JL; Moore AL; Dorighi JA; Grant BW; Haugh LD; Roberts JD; Albertini RJ; Branda RF
Cancer Res; 1990 Oct; 50(19):6302-10. PubMed ID: 2205379
[TBL] [Abstract][Full Text] [Related]
15. Phenotype and function of natural killer cells in patients with bronchogenic carcinoma.
LeFever AV; Funahashi A
Cancer Res; 1991 Oct; 51(20):5596-601. PubMed ID: 1655257
[TBL] [Abstract][Full Text] [Related]
16. Recombinant interleukin-2 and lymphokine-activated killer cell treatment of advanced bladder cancer: clinical results and immunological effects.
Hermann GG; Geertsen PF; von der Maase H; Steven K; Andersen C; Hald T; Zeuthen J
Cancer Res; 1992 Feb; 52(3):726-33. PubMed ID: 1732060
[TBL] [Abstract][Full Text] [Related]
17. A pilot study of intralymphatic interleukin-2. I. Cytotoxic and surface marker changes of peripheral blood lymphocytes.
Shau H; Isacescu V; Ibayashi Y; Tokuda Y; Golub SH; Fahey JL; Sarna GP
J Biol Response Mod; 1990 Feb; 9(1):71-80. PubMed ID: 2319261
[TBL] [Abstract][Full Text] [Related]
18. Serum and acute phase protein modulation of the effector phase of lymphokine-activated killer cells.
Clayman GL; Taylor DL; Liu FJ; Lavedan P; Savage HE; Schantz SP
Laryngoscope; 1993 Mar; 103(3):299-307. PubMed ID: 7680086
[TBL] [Abstract][Full Text] [Related]
19. Enrichment in tumor-reactive CD8+ T-lymphocytes by positive selection from the blood and lymph nodes of patients with head and neck cancer.
Letessier EM; Heo DS; Okarma T; Johnson JT; Herberman RB; Whiteside TL
Cancer Res; 1991 Aug; 51(15):3891-9. PubMed ID: 1677310
[TBL] [Abstract][Full Text] [Related]
20. The phenotypic changes in tumour infiltrating lymphocytes and tumour cells following intra-arterial infusion of interleukin-2 in patients with squamous cell carcinoma.
Salter J; Maclennan KA; Moore J; Dadian G; Riches PG; Gore ME
J Pathol; 1995 Jun; 176(2):167-73. PubMed ID: 7636627
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
